Max Mamonkin (@maxmamonkin) 's Twitter Profile
Max Mamonkin

@maxmamonkin

Engineering CART for cancer and alloimmunity. Translating to Phase I clinical trials @cagthouston @bcmhouston

ID: 856179633686970368

linkhttps://www.bcm.edu/people-search/maksim-mamonkin-26041 calendar_today23-04-2017 16:15:06

485 Tweet

1,1K Followers

266 Following

Dimitrios L. Wagner (@dlwagner13) 's Twitter Profile Photo

🚀 Join Our Team at Baylor College of Medicine! 🧬 We’re looking for passionate technician to join our lab at Center for Cell and Gene Therapy. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing. Pls RT 🙏 jobs.bcm.edu/job/Research-T…

Max Mamonkin (@maxmamonkin) 's Twitter Profile Photo

Like many disruptive technologies, engineered T-cell therapies follow the Gartner hype cycle. We are approaching the second upward slope.

Like many disruptive technologies, engineered T-cell therapies follow the Gartner hype cycle. We are approaching the second upward slope.
Max Mamonkin (@maxmamonkin) 's Twitter Profile Photo

Matt Rea was treated with CD19 CART cells back in 2010 at Baylor Center for Cell and Gene Therapy and has been cancer-free since then, for 14 years. The CAR-T were made from his twin brother. Is he the longest surviving CAR-T patient? blogs.bcm.edu/2024/06/04/fol…

Max Mamonkin (@maxmamonkin) 's Twitter Profile Photo

The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor Center for Cell and Gene Therapy and still remains in remission. We need more of these stories. researchsquare.com/article/rs-423…

Marco Ruella (@marcoruella) 's Twitter Profile Photo

Congrats to the now Dr. Ruchi Patel for the publication of her PhD thesis in Science Immunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. Penn Medicine Ruella Lab science.org/doi/10.1126/sc…

Max Mamonkin (@maxmamonkin) 's Twitter Profile Photo

T cells express a ton of CD5, so why CD5 CAR T cells don't kill each other? Turns out, they completely degrade CD5 protein and thus evade fratricide. Unique mechanism unveiled in a mechanistic study - and PhD thesis work - by Royce Ma: cell.com/cell-reports-m…

Max Mamonkin (@maxmamonkin) 's Twitter Profile Photo

An interesting POC of T cell therapy in CNS injury models: autoreactive MOG-specific T cells infiltrate the lesion and suppress tissue damage, counter-intuitively in part via IFNg secretion. But you have to act fast. nature.com/articles/s4158…

Max Mamonkin (@maxmamonkin) 's Twitter Profile Photo

Great step forward in humanized mouse models. Using iPSC-derived CD34+ iHSC which engraft and produce human multi-lineage progeny in immunodeficient NBSGW mice nature.com/articles/s4158…

Michael Birnbaum (@mebirnbaum) 's Twitter Profile Photo

My department (MIT Biological Engineering) is hiring at the Assistant Professor level! We are looking for someone in immunology/immunotherapy/immune engineering, broadly defined. be.mit.edu/about/open-fac…

Peggy Goodell (@goodell_lab) 's Twitter Profile Photo

Recruiting faculty to the Dept of Molecular and Cellular Biology at Baylor College of Medicine in Houston, TX! Recruiting broadly in cancer and cell biology. Submit by October 1, 2024, for full review. #cellbio @BCMhouston bcm.edu/departments/mo… jobs.sciencecareers.org/job/659987/ten…

Dimitrios L. Wagner (@dlwagner13) 's Twitter Profile Photo

Preprint alert 🚨 Up to 90% CAR knock-in rates in primary human T cells - without drug enhancers? 🧐 Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells biorxiv.org/content/10.110… 🧵👇

Columbia Medicine (@columbiamed) 's Twitter Profile Photo

Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center. ➡️columbiamed.link/3zCR9iI

Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center.

➡️columbiamed.link/3zCR9iI
Justin A. Guerrero (@dr_jguerrero) 's Twitter Profile Photo

I am very pleased to announce the work I did as a graduate student in the labs of Crystal Mackall and Everett Meyer has been published in Nature Communications, open access! nature.com/articles/s4146…

Heczey Lab (@heczeylab) 's Twitter Profile Photo

IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer). nature.com/articles/s4158…